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Cholesterol 25-hydroxylase (CH25H) as an interferon-stimulated gene (ISG) has recently been shown to
exert broad antiviral activity through the production of 25-hydroxycholesterol (25HC), which is believed to
inhibit the virus-cell membrane fusion during viral entry. However, little is known about the function of
CH25H on HCV infection and replication and whether antiviral function of CH25H is exclusively mediated
by 25HC. In the present study, we have found that although 25HC produced by CH25H can inhibit HCV
replication, CH25H mutants lacking the hydroxylase activity still carry the antiviral activity against HCV
but not other viruses such as MHV-68. Further studies have revealed that CH25H can interact with the
NS5A protein of HCV and inhibit its dimer formation, which is essential for HCV replication. Thus, our
work has uncovered a novel mechanism by which CH25H restricts HCV replication, suggesting that CH25H
inhibits viral infection through both 25HC-dependent and independent events.
H
epatitis C virus (HCV) has infected 170 million people worldwide1. Exposure to HCV after acute infection
often leads to a chronic infection in the liver, eventually causing cirrhosis and hepatocellular carcinoma2–3.
HCV possesses a 9.6-kb positive-sense RNA genome and its genome encodes a single polyprotein com-
posed of approximately 3,000 amino acids which is processed by host and viral proteases, resulting in 10 viral
proteins4. The nonstructural protein 5A (NS5A) is a 56-59–kDa phosphoprotein with an N-terminal amphipathic
alpha helix (amino acids 5–25), and 3 structural domains (I, II and III) that is absolutely required for both RNA
replication and virus assembly5–6.
Type-I interferons (IFNs), which include IFNa, -b, and –v, are rapidly induced during viral infection and play
a central role in restricting virus replication through the induction of a wide array of anti-viral effectors7–8.
Hundreds of interferon stimulated genes (ISGs) have been identified since their discovery more than 25 years
ago, and multiple ISGs have been reported to interfere with various key steps of HCV lifecycle via different
mechanisms9–10. For example, ISG56 primarily inhibits HCV replication11, while IFITM1 has been shown to
suppress both entry and replication process of the virus11–12. On other hand ISG20 and PKR are reported to inhibit
HCV RNA synthesis depending on their 39-59 exonuclease and protein kinase activities, respectively13, while
ISG15 was reported to inhibit HCV replication by decreasing the NS5A stability14. However, function of many
other ISGs on HCV infection and replication remain to be elucidated. Cholesterol-25-hydroxylase (CH25H) is a
31.6-kDa endoplasmic reticulum-associated enzyme that catalyzes oxidation of cholesterol to 25-hydroxycho-
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element binding protein processing15–16. CH25H is reported to be a
conserved ISG, which is rapidly induced in many tissues including
the liver, heart, brain, muscle, kidney and lung upon in vivo exposure
to various toll-like receptor (TLR) ligands and IFN molecules17.
Recently, CH25H has been identified as a major antiviral factor
through producing 25HC, which is shown to inhibit a diverse array
of viruses, including enveloped viruses (VSV, HSV, HIV, and
MHV68) and acutely pathogenic EBOV, RVFV, RSSEV, and
Nipah viruses by blocking membrane fusion between virus and cell18.
Another study using quantitative metabolomic profiling also
demonstrated that 25HC is the only secreted oxysterol synthesized
by macrophages to act as a potent paracrine inhibitor of viral infec-
tion for a broad range of viruses at multiple levels19. Although 25HC
has also been reported to possess anti-HCV activity20–21, the function
of CH25H on HCV replication, and whether antiviral function of
CH25H is exclusively mediated by 25HC are currently unknown.
In the present study, we show that CH25H has novel antiviral
effects on HCV replication not only through its enzyme activity to
produce 25HC but also by targeting NS5A leading to the selective
inhibition of NS5A dimer formation.
Results
CH25H and its products suppress HCV infection. To study the
function of CH25H on HCV infection, the plasmid co-expressing
CH25H and the red fluorescent protein RFP (linked by IRES) was
transfected into Huh7.5.1 cells and the cells were subsequently
infected with HCV GFP reporter virus (HCV-GFP). Expression of
CH25H and replication of HCV were analyzed and measured by
FACS based on RFP and GFP signals. The RFP positive population
(RFP1) identifies cells that highly express CH25H, whereas the RFP
negative population (RFP-) represents cells that do not express
CH25H (Fig. 1A). Interestingly, overexpression of CH25H
inhibited HCV infection not only in the RFP1 population of cells,
but also in RFP- cells, suggesting that CH25H produces a soluble
factor that can confer a cell non-autonomous anti-viral activity onto
other adjacent cells (Fig. 1B and C). It was reported that expression
levels of CH25H at steady-state are low-to-undetectable in most
tissues and cells22, we then detected the expression of CH25H in
293T, Huh7.5.1 and Replicon cells by western blotting and the
result showed that the endogenous expression of CH25H is very
weak (see Fig. S1 in the supplemental material). CH25H catalyzes
oxidation of cholesterol to 25-hydroxycholesterol (25HC), which is a
soluble oxysterol that modulate cellular functions in both autocine
and paracrine fashions. To determine whether transfection of
CH25H led to the production of a soluble antiviral factor, we
performed conditioned medium experiment. HEK293T cells were
transfected with CH25H or vector control, and the conditioned
medium was transferred onto freshly plated Huh7.5.1 cells for
Figure 1 | CH25H and its products suppress HCV infection. A: Schematic diagram of FACS analysis of HCV-GFP in total, RFP1, RFP- populations.
Relative replication of HCV-GFP reporter virus is defined as GFP1% x the geometric mean fluorescence intensity (MFI). B: Contour maps of HCV-GFP
replication in Huh7.5.1 cells transfected with the indicated RFP-ISG. C: Effect of overexpression of RFP-CH25H on HCV-GFP replication in total, RFP-
positive or negative population normalized to vector control. HCV-GFP was quantified by the calculated value of the percentage % GFP-positive
population and MFI of GFP signal. D: Medium was collected from HEK293T cells after 48 h transfection with indicated expression vectors. Freshly plated
Huh7.5.1 cells were treated with the conditioned medium for 8 h and then infected with HCV-GFP at 0.2MOI. HCV-GFP was quantified by FACS at
48 hpi. E: Huh7.5.1 cells were pretreated with increasing amounts of 25HC (0, 1, 5 uM) for 8 h. HCV-GFP infection and quantification were measured at
48 and 72 hpi. All experiments were performed in triplicates and data shown are representative of three independent experiments with SEM indicated by
error bars. *P , 0.05; **P , 0.01; ***P , 0.001.
www.nature.com/scientificreports
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12 hr before infection with HCV-GFP reporter virus (0.2 MOI). The
result showed that the conditioned medium from CH25H
transfected HEK293T cells generated ,50% HCV inhibition
(Fig. 1D). Consistently, treatment of Huh7.5.1 cells with 25-
hydroxycholesterol molecule also led to significant inhibition of
HCV infection dose-dependently (Fig. 1E). The effect of 25HC on
cell viability was also assessed and the result showed that 25HC
treatment at 5 uM did not affect cell viability (see Fig. S2 in the
supplemental material). Taken together, these data suggest that
CH25H and its products could inhibit HCV infection in liver cells.
CH25H and its products suppress HCV replication. To further
investigate how HCV replication was affected by CH25H, Huh-7
cells harboring an HCV subgenomic replicon mimicing the viral
RNA replication23 was used for the study. Dual immunofluorcence
staining for HCV antigen (NS3) and CH25H was performed to
examine the expression of the replicon proteins and effect of
CH25H. The result clearly showed that a much lower level of HCV
NS3 expressed in those cells which were positive of CH25H
expression (Fig. 2A). Transfection of CH25H also decreased HCV
RNA levels in HCV replicon cells which demonstrated that enforced
expression of CH25H could directly inhibit HCV RNA replication
(Fig. 2B). We also examined the effect of 25-hydroxycholesterol on
HCV RNA replication, and the result showed that HCV replicon
activity was indeed inhibited by 25-hydroxycholesterol in a dose-
dependent manner. (Fig. 2C and D). These results indicated that
anti-HCV activity of CH25H can be mediated by its enzymatic
product, 25-hydroxycholesterol.
Mutant forms of CH25H can inhibit HCV replication indepen-
dent of its enzyme activity. CH25H is a member of a small family of
molecules that uses diiron cofactors to catalyze the hydroxylation of
hydrophobic substrates. Clustered histidine residues in CH25H were
reported to be important for its enzyme activity24. To delineate the
anti-HCV mechanism of CH25H, a pair of histidine codons at
positions 242 and 243 in the human CH25H were mutated to
glutamine codons by site-directed mutagenesis. Liquid Chromato-
graphy Mass Spectrometry (LC-MS/MS) experiment was performed
to determine whether the mutant form of CH25H (CH25H-M) has
lost the ability to produce 25HC. LC-MS/MS results showed that
while abundant 25HC was present in the conditioned medium
from cells expressing wildtype CH25H, none was detected in the
CH25H-M expressing conditioned medium (see Fig. S3 in the
supplemental material), confirming that the enzyme activity is
indeed disrupted in CH25H-M. To examine the HCV inhibitory
activity of CH25H-M, we performed the similar cell autonomous
and cell non-autonomous test experiment as described in Fig 1.
We found that while expression of CH25H from RFP-linked
Figure 2 | CH25H and its products suppress HCV subgenomic replicon replication. A: Effect of CH25H on HCV replication. JFH HCV Replicon cells
were transfected with HA-CH25H expression plasmid and immunofluorescence staining performed 48 hours later using a rabbit polyclonal anti-HA
antibody and a mouse monoclonal anti-NS3 antibody, followed by an FITC-conjugated goat anti-rabbit and a TRITC-conjugated goat anti-mouse
secondary antibodies. Red fluorescence shows NS3 staining, while green fluorescence detects CH25H. B: Effect of CH25H on HCV RNA expression. The
CH25H expression plasmid or vector control plasmid was transfected into JFH replicon cells. Total RNA was extracted 48 hours after transfection and
quantified by real-time RT-PCR. C: Effect of 25HC on HCV replication. Replicon cells were treated with increasing amounts of 25HC (0, 1, 5 uM) for
24 h (C) or 48 h (D). HCV Replicon RNA was quantified by real-time RT-PCR. All experiments were performed in triplicates and data shown are
representative of three independent experiments with SEM indicated by error bars. *P , 0.05; **P , 0.01; ***P , 0.001.
www.nature.com/scientificreports
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expressing vector resulted in the inhibition of HCV infection in the
RFP negative population of cells, CH25H-M failed to do so (Fig. 3A)
indicating that cell non-autonomous inhibition of HCV infection in
RFP negative cells requires the enzymatic activity of CH25H. Inte-
restingly, however, the CH25H-M still inhibited HCV infection in
RFP positive population of cells suggesting that CH25H can also
inhibit HCV infection in cell autonomous fashion via hydroxylase
independent mechanism. To further investigate whether the 25HC-
independent antiviral mechanism of CH25H operates selectively for
HCV infection, we conducted viral inhibition assays with another
virus MHV-68. The result showed that in contrast to HCV, CH25H-
M failed to inhibit MHV-68 infection (see Fig. S4 in the supplemental
material). Thus the alternative hydroxylase-independent antiviral
mechanism of CH25H acts selectively in the context of HCV infec-
tion. Next, we investigated which domains of CH25H, including
Transmembrane (TM) domain and FAase (FA) domain, are respon-
sible for its inhibitory effect on HCV replication. We found that both
TM and FA domains could inhibit HCV replication (Fig. 3C). The
conditioned medium from the cells transfected with CH25H or the
truncated mutants was transferred onto freshly plated HCV Replicon
cells to test their effect on HCV RNA replication. The result showed
that while the conditioned medium from CH25H generated ,50%
HCV RNA inhibition, the medium from cells expressing the mutants
had no antiviral function on HCV replication, thus further proved
that indeed the enzymatic function of CH25H is not sufficient for its
anti-HCV activity (Fig. 3D). Taken together, our results demon-
strated that CH25H can inhibit HCV infection and replication
independent of its enzyme activity.
CH25H selectively interacts with HCV NS5A. To study how
CH25H inhibits HCV replication independent of its enzyme
activity, we studied the interactions between CH25H and virus
encoded proteins using Bi-molecular fluorescence complementa-
tion (BiFC) assay and found that CH25H interacted with NS5A
(see Fig. S5 in the supplemental material). To further examine the
interaction between NS5A and CH25H, Coimmunoprecipitation
(Co-IP) experiments were performed by co-transfection of HA-
tagged CH25H and Flag-tagged NS5A expression plasmids. The re-
sults showed that NS5A indeed interacted with CH25H (Fig. 4A). To
further confirm their interaction inside cells, immunofluorescent
microscopy analysis was conducted. Two-color immunofluore-
scent staining showed that CH25H and NS5A were indeed largely
colocalized in the distinct cytoplasmic compartment (Fig. 4B).
Having confirmed the molecular interaction between NS5A and
CH25H, we subsequently carried out protein truncation assays to
map the interaction regions of CH25H and NS5A. We constructed
expression plasmids for the truncated proteins according to the
reported domain structure of NS5A and CH25H, which were the
Figure 3 | CH25H can inhibit HCV replication independent of its enzyme activity. A: Effect of enforced expression of RFP-CH25H or RFP-CH25H-M
plasmid on HCV-GFP in RFP-positive or negative population normalized to vector control. HCV-GFP was quantified as in Fig 1A. B: Effect of enforced
expression of CH25H and its truncation mutants on HCV replication. The indicated CH25H-expression constructs were transfected into JFH replicon
cells. Total RNA was extracted 48 hours after transfection and quantified by real-time RT-PCR. C: The conditioned medium was collected from
HEK293T cells after 48 h transfection with indicated expression vector. Freshly plated Replicon cells were treated with conditioned medium for 24 h and
total RNA were extracted and quantified by real-time RT-PCR. All experiments were performed in triplicates and data shown are representative of three
independent experiments with SEM indicated by error bars. *P , 0.05; **P , 0.01. All the gels were run under the same experimental conditions as
detailed in the Methods section, and full-length blots were cropped for final display.
www.nature.com/scientificreports
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domain I and domain II/III for NS5A, and the Transmembrane
(TM) and FAase (FA) for CH25H. Coimmunoprecipitation
experiments showed that the domain I but not domain II/III of
NS5A interacted selectively with both TM and FA domains of
CH25H (Fig. 4C and D), indicating the domain I of NS5A is
distinctly targeted by CH25H.
CH25H specifically disrupts NS5A dimer formation. The domain
I of NS5A has been reported to be responsible for the formation of
NS5A homo-dimer, which is crucial for HCV viral RNA synthesis
and replication25–26. We thus hypothesized that CH25H binding to
NS5A domain I interferes NS5A dimer formation. To test this
hypothesis, we performed competitive coimmunoprecipitation
experiments. The results demonstrated that CH25H could
indeed disrupt the formation of NS5A dimer in a dose-
dependent manner (Fig. 5A lane 4 and 5). To further establish
the relationship of NS5A dimer disruption and inhibition of HCV
replication, we carried out extended experiment to examine the
effect of the CH25H mutants on NS5A dimer formation. The
results showed that consistently CH25H-M and the truncated
mutants all could disrupt NS5A dimer formationas potent as
was the wildtype CH25H (Fig. 5A lane 6-lane 9). Collectively,
our results showed that NS5A dimer formation could be
inhibited by CH25H and its TM and FA domains suggesting
that disruption of NS5A dimer is a critical mechanism how
CH25H inhibits HCV replication.
Figure 4 | CH25H interacts with HCV NS5A. A: NS5A interacts with CH25H. Expression vectors for Flag-tagged NS5A and HA-tagged CH25H were
transfected into HEK293T cells. After 36 h, the cells were harvested and lysed, and then the whole cell extracts were subjected to Co-IP assay using an anti-
Flag M2-agarose. B: Colocalization of CH25H with NS5A. HEK293T cells were co-transfected with Flag-tagged NS5A and HA-tagged CH25H. After 36 h,
the cells were fixed and stained with anti-Flag or anti-HA antibody, followed by TRITC- or FITC-conjugated anti-mouse or anti-rabbit secondary
antibody, then analyzed by confocal microscopy and the Pearson’s Coefficient is 0.86473. C: CH25H and CH25H-M interact with domain I of NS5A.
Expression plasmids for HA-tagged CH25H or CH25H-M were co-transfected with Flag-tagged NS5A truncation mutant constructs. Co-IP assays were
performed using cell lysates from cells expressing the indicated constructs. D: Both of TM and FA domains of CH25H interact with NS5A. Expression
plasmids for HA-tagged CH25H TM or FA domain were co-transfected with Flag-tagged NS5A. Co-IP assays were done as in C. All results were confirmed
by three independent experiments. All the gels were run under the same experimental conditions as detailed in the Methods section, and full-length blots
were cropped for final display. Full-length blots are included in the supplementary information.
www.nature.com/scientificreports
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To further validate the notion that competitive binding of CH25H
to NS5A is indeed responsible for the inhibition of HCV replication,
we co-transfected NS5A and CH25H or CH25H-M plasmids into
HCV replicon cells and measured the replicon RNA levels. We found
that overexpression of NS5A rescued HCV replication inhibited by
CH25H or CH25H-M, while another HCV encoded protein NS4A
which does not bind to CH25H failed to do so (Fig. 5B and C).
Therefore, these data collectively demonstrated that CH25H inhibits
HCV replication by binding to NS5A selectively.
Discussion
The current combination therapy for chronic hepatitis C virus
(HCV) infection includes Type 1 interferon (IFN) which induces a
wide array of interferon-stimulated genes (ISGs) to inhibit virus
infection27. ISGs work to restrict viral infection through a wide vari-
ety of mechanisms, however, only a few ISGs have so far been defined
to have anti-HCV properties. An understanding of the mechanisms
by which ISGs exert their inhibitory activities against HCV would
enrich the treatment modalities to improve the effectiveness of the
current anti-HCV therapeutics while reducing unwanted side effect.
In this work, we define CH25H as an anti-HCV effector ISG that
can potently inhibit HCV infection and replication (Fig. 1 and 2).
CH25H is an enzyme that catalyzes oxidation of cholesterol to 25-
hydroxycholesterol (25HC)24. However, little is known about the
functional aspects of CH25H that contribute to its antiviral activity.
Recent work has started to reveal that CH25H inhibits VSV and HIV
infection at the level of viral entry, specifically by inhibiting the virus-
cell membrane fusion through the production of 25HC18. 25HC was
also previously reported to inhibit HCV replication20 which is con-
sistent with our data that CH25H inhibits HCV infection and rep-
lication partly dependent on the enzyme activity to produce 25HC.
25HC belongs to a diverse class of endogenous oxysterols, the oxida-
tion products of cholesterol, which is well characterized as a soluble
factor that control fatty acid biosynthesis through regulation sterol-
responsive element binding proteins (SREBP)15. It was also identified
to bind and activate the nuclear hormone receptor liver X receptors
(LXR)28. LXRs play an important role on lipid metabolism and were
reported to control the low-density lipoprotein (LDL) receptor
(LDLR) expression29–30, suggesting that 25HC could inhibit LDLR
expression. Recent studies demonstrated that hepatocytes treated
Figure 5 | CH25H disrupts NS5A dimer formation. A: Co-IP assays using Flag control vector or Flag-tagged full-length NS5A as bait to capture YFPn-
tagged NS5A domain I were performed in the presence of an increasing amount of HA-tagged CH25H, HA-tagged CH25H-M, or HA-tagged CH25H
truncation mutant constructs. Captured proteins were analyzed by Westernblot using anti-GFP and anti-Flag antibodies. All results were confirmed by
three independent experiments. All the gels were run under the same experimental conditions as detailed in the Methods section, and full-length blots
were cropped for final display. Full-length blots are included in the supplementary information. Effects of NS5A or NS4A on antiviral activities of CH25H
(B) or CH25H-M (C). The indicated plasmids expressing control, NS5A or NS4A expression plasmids were cotransfected with CH25H wt or mutant
CH25H expression plasmids into Replicon cells. HCV RNA level was measured by real-time RT-PCR 48 hours after transfection. All experiments
were performed in triplicates and data shown are representative of three independent experiments with SEM indicated by error bars. *P , 0.05.
www.nature.com/scientificreports
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with 25HC exhibited decreased LDLR mRNA levels31. LDLR is a
membrane glycoprotein which has been reported to be essential
for replication of the HCV genome32. Our preliminary study result
also showed that CH25H could inhibit LDLR expression which
might provide an explanation for 25HC mediated antiviral function
on HCV.
In an attempt to delineate the anti-HCV mechanism of CH25H,
we generated a mutant CH25H construct lacking enzymatic activity
to produce 25HC. Although the enzymatic dead mutant CH25H-M
failed to produce 25HC and was unable to inhibit HCV infection in
trans by the paracrine mechanism, however, the mutant CH25H still
inhibits HCV infection in RFP positive population (Fig. 3A), and
overexpression of CH25H but not CH25H-M inhibits MHV-68
growth. All truncations of CH25H not the conditional medium
inhibit HCV replication (Fig. 3B and C) confirming that an alterna-
tive antiviral mechanism for the protein specifically in the context of
HCV is independent on its enzyme activity.
NS5A is a pleiotropic virus-encoded protein required for HCV
RNA replication33. The structure of Domain I suggests that it is
dimeric in nature which forms a positively charged groove involved
in RNA binding25. Recently several studies have shown that the NS5A
dimer formation mediated by domain I is essential for HCV replica-
tion26,34. Therefore it is an attractive target for direct antiviral therapy
of HCV35. The remarkably potent RNA replication inhibitor, BMS-
790052, has been implicated to target NS5A by inhibiting its dimer-
ization36. Viperin, one conserved type I ISG, was also reported to
inhibit HCV replication by interacting with NS5A37–38. Using BiFC
screening system we demonstrated that CH25H specifically interacts
with HCV NS5A, not other viral proteins including Core, NS3, NS4A
or NS5B. Co-IP data demonstrated that both TM and FA domains of
CH25H interact with the domain I of NS5A (Fig. 4). Thus CH25H
binds to the same domain of NS5A responsible for dimer formation,
suggesting that competition for dimer formation may serve as a
strategy for host to inhibit HCV replication. Indeed, we showed that
NS5A dimerization was strongly disrupted in the presence of CH25H
or the mutant forms of CH25H which remain activity in HCV inhibi-
tion, even though lacking hydroxylase activity (Fig. 5A). At the same
time, our results also confirmed the importance of the dimer forma-
tion of NS5A in HCV replication. We have further substantiated this
finding by showing that overexpression of NS5A but not other HCV
viral proteins, such as NS4A could rescue the inhibition of HCV
replication imposed by CH25H or CH25H-M (Fig. 5B and C), con-
firming that CH25H inhibits HCV replication by competitive bind-
ing with NS5A. In addition to its essential function in HCV RNA
synthesis and replication, NS5A also attracts considerable interest
because of its potential role in evading host defense by modulating
the response to IFN-a therapy. One of the critical genetic determin-
ant for IFN resistant of various HCV genotypes is mapped to the
region in NS5A called the interferon-a sensitivity-determining
region (ISDR). It will be interesting to test in future work whether
the adaptive mutations found in this region affect the interaction
between CH25H and NS5A.
In conclusion, the work presented herein has extended our under-
standing of the newly identified antiviral protein CH25H. The find-
ings described here as well as reported by others clearly show that
CH25H can broadly suppress virus infection by producing
25HC18–19. Nevertheless, we have identified another novel antiviral
mechanism to HCV independent of its enzyme activity by specif-
ically binding to NS5A and inhibiting its dimer formation, suggesting
that CH25H is a multiple functional antiviral protein which is able to
inhibit viral infection and replication through both 25HC-dependent
and independent pathways. Taken together, our work sheds inter-
esting light on the mechanisms by which CH25H restricts HCV
replication and also points out a potential new strategy to improve
the existing anti-HCV therapies by effectively inducing CH25H
expression and function.
Methods
Reagents and Antibodies. Mouse monoclonal and rabbit polyclonal antibodies
against FLAG (Sigma), HA (Sigma), mouse monoclonal antibodies against b-actin
(Sigma), NS3 (Abcam) and rabbit polyclonal antibody against GFP (Abcam), 25-
hydroxycholesterol (Sigma) were purchased from the indicated companies.
HCV Replicon Cells and HCV-JFH1 Cell Culture. HCV replicon cells (JFH strain)
from Dr. Jin Zhong were maintained in complete DMEM supplemented with 0.5 g/L
G418 (Invitrogen). The human hepatocellular carcinoma cell line Huh7.5.1 and
HCVJFH1-infected Huh7.5.1 cells were maintained in complete DMEM. The
Huh7.5.1 cells were infected with GFP-HCV (JFH1 strain) as previously described39.
Plasmids and Expression Vectors. Mammalian expression plasmids for full-length
wildtype human CH25H (aa1-aa272), CH25H TM domain (aa1-aa135) and CH25H
FAase domain (aa136-aa272) were PCR and cloned into pCMV-HA to generate HA
tagged expression constructs by standard molecular cloning techniques. Site-directed
mutagenesis was carried out to convert histidine codons at positions 242 and 243 of
the wildtype CH25H to glutamine codons according to manufacturer instructions
(TransGen Biotech) to create the mutant form (CH25H-M) deprived of catalytic
activity. Sequences encoding full-length HCV NS5A (aa1978-aa2458), NS5A domain
I (aa1978-aa2173), NS5A domain II and III (aa2174-aa2458) and NS4A (aa1683-
aa1715) were amplified by PCR from a plasmid encoding the full-length genome of
JFH-1 HCV and cloned into pENTR/D-TOPO vector (Invitrogen). Through
Gateway recombination, the NS5A ORF fragments cloned in pENTR/D-TOPO were
transferred individually into pL-EF1a-DEST-Flag or pBabe-CMV-YFPn-DEST-neo
expression vectors described in40 to generate C-terminal Flag-tagged or YFPn-tagged
full length or truncated NS5A constructs. Similarly, the ORFs of CH25H and CH25H-
M were transferred into pL-EF1a-DEST-SFB-IRES/TagRFP expression vector to co-
express target gene and IRES-linked RFP marker. Primer pairs used for PCR
amplification of the genes are listed (see Table S1 in the supplemental material). The
target genes in the resulting Gateway expression plasmids were all confirmed by DNA
sequencing, diagnostic restriction enzyme digestion analyses, and further by
westernblot.
Transfection. Plasmid transfections were performed using Lipofectamine 2000
following the manufacturer’s instructions (Invitrogen).
Immunofluorescence staining. Cells were fixed in 4% paraformaldehyde,
permeabilized with 0.2% Triton X-100/PBS before incubation with primary
antibodies (anti-NS3, anti-HA or anti-Flag) for 1 hour at room temperature (RT).
Cells were washed in PBS, followed by incubation with TRITC or FITC-conjugated
anti-mouse or anti-rabbit immunoglobulin (Ig) secondary antibodies. Nuclei were
stained with DAPI. Confocal microscopy was performed with Olympus FV1000
Confocal Microscope (Olympus).
Flow cytometry. Cells were collected by trypsinization, fixed in 2%
paraformaldehyde and analyzed on BD FACS-Calibur flow cytometer (BD
Biosciences).
Quantitative RT–PCR (qPCR) analysis. Total RNA was extracted from cultured
cells with TRIzol reagent (Invitrogen). Real-time PCR was performed with Power
SYBR Green PCR master mix (Applied Biosystems) in an ABI 7500 Real-time PCR
system (Applied Biosystems). The primers for real-time PCR are as follows: JFH-
HCV (Forward, 59-TCTGCGGAACCGGTGAGTA-39; Reverse, 59-
TCAGGCAGTACCACAAGGC-39); GAPDH (Forward, 59-
GAACGGGAAGCTCACTGG-39; Reverse, 59-GCCTGCTTCACCACCTTCT-39).
All gene expression data were normalized to the expression of GAPDH.
Co-immunoprecipitation and Western Blot Analysis. Cells were lysed 36–48 h
after transfection of expression plasmids using 50 mM Tris–HCl, pH 8.0, 150 mM
NaCl, 1% Triton X-100 containing cocktail. For immunoprecipitation, lysates were
incubated with the appropriate antibodies for 2 h on ice, followed by precipitation
with protein G Sepharose (Santa Cruz). Samples were separated by SDS–PAGE and
transferred to PVDF membranes. After blocking in PBS containing 0.1% Tween-20
and 5% skim-milk, the blots were probed with indicated antibodies. Westernblot
visualization was done with enhanced chemiluminescence.
Quantification of 25-Hydroxycholesterol. 2 mL of cell culture medium was
extracted with 5 mL of methanol and 1 g of sodium sulfate anhydrous (Na2SO4)
twice. After centrifugation, the supernatant was evaporated to dryness with nitrogen
gas flow. The residue was reconstituted with 0.5 mL of acetonitrile and 0.5 mL of
water and analyzed by LC-MS/MS with ESI1 ion source (API 5000, Applied
Biosystems, ON, Canada). The instrument procedure follows the description41.
MHV-68 infection. HEK293T cells were infected with MHV-68(M3FL)42 at
MOI50.25. After 24hpi, the supernatant was tansferred to naı̈ve BHK21 and
luciferase activity was measured at 9hpi.
Statistical methods. GraphPad Prism 5 software (GraphPad Software, San Diego,
CA) was used for data analysis using a two-tail unpaired t test. A p value ,0.05 was
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